Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxygen Study: Orelabrutinib + Obinutuzumab for MZL
NCT06566807Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in marginal zone lymphoma (MZL). Started Aug 2024; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06566807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566807.